RNA interference (RNAi) screening approach identifies agents that enhance paclitaxel activity in breast cancer cells

Table 2 Top gene targets from siRNA screen that increase paclitaxel sensitivity and the corresponding chemical inhibitors

	MDA-MB-231	MDA-MB-468		Previous combination with paclitaxel
Gene	Mean SI	Mean SI	Drug/chemical inhibitor	Pre- clinical	Clinical	Ref
PPM1D	0.055	0.136	thioxanthen-9-one; CCT007093; anti-estrogens*	no	no
CENPF	0.049	0.113	farnesyltransferase inhibitors*	yes	yes	[62, 68, 69]
BCL2L1	0.041	0.093	ABT-737; AT-101	yes	no	[63, 64]
FRAP1	0.037	0.078	rapamycin; RAD001	yes	yes	[58, 59]
IGF1	0.038		NVP-AEW541; 9-cis-retinoic acid; raloxifene	yes	no	[67]
EGFR		0.154	erlotinib; gefitinib; cetuximab	yes	yes	[54, 60, 61]
ERK1		0.148	ERK/MEK inhibitors	yes	no	[65, 66]
RPS6KB1		0.140	rapamycin; RAD001	yes	yes	[58, 59]
TGFB1		0.121	LY2109761; LY2157299; SD-208	no	no
SP1		0.085	mithramycin; arsenic trioxide*	no	no

ISSN: 1465-542X